Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy (Q37829385)

24 August 2017

1 reference

title

Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy (English)

1 reference

24 August 2017

1 reference

1 reference

4

Roberto Gerli

1 reference

24 August 2017

Elena Bartoloni

1

1 reference

PubMed ID

21240669

24 August 2017

Alessia Alunno

series ordinal

2

1 reference

PubMed ID

21240669

24 August 2017

Onelia Bistoni

series ordinal

3

1 reference

24 August 2017

1 February 2013

1 reference

Clinical Reviews in Allergy & Immunology

24 August 2017

1 reference

24 August 2017

44

1 reference

24 August 2017

1

1 reference

24 August 2017

14-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-010-8251-x

24 August 2017

0 references

cites work

Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006.

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Accelerated atherosclerosis in autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiac involvement in systemic rheumatic diseases: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Functional impairment of the arterial wall in primary Sjögren's syndrome: combined action of immunologic and inflammatory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

How early is the atherosclerotic risk in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Patterns of cardiovascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Inflammation in atherosclerosis: transition from theory to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular risk factors, fitness and physical activity in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Statin treatment for rheumatoid arthritis: a promising novel indication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

The scleroderma kidney: progress in risk factors, therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Insulin resistance in early untreated rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular co-morbidity in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Effect of glucocorticoids on the arteries in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8251-X

Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al

21 January 2018

1 reference

12 December 2020

Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate

1 reference

12 December 2020

Effect of tumor necrosis factor alpha inhibition on CD28 surface expression on CD4+ T cells

1 reference

12 December 2020

The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006

1 reference

12 December 2020

Traditional cardiovascular risk factors in primary Sjögren's syndrome--role of dyslipidaemia

1 reference

12 December 2020

Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis

1 reference

12 December 2020

Precocious intima-media thickening in patients with primary Sjögren's syndrome

1 reference

12 December 2020

Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study

1 reference

12 December 2020

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

12 December 2020

Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases

1 reference

12 December 2020

Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis

1 reference

12 December 2020

Vascular function and inflammation in rheumatoid arthritis: the role of physical activity

1 reference

12 December 2020

The metabolic syndrome in systemic lupus erythematosus

1 reference

12 December 2020

10.1007/S12016-010-8251-X

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21240669